Polyethylene glycol

Autologous Matrix-Induced Chondrogenesis (AMIC) Report 2021 - Global Market Trajectory & Analytics 2012-2019 & 2020-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021

The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Hyaluronic Acid, one of the segments analyzed in the report, is projected to record a 7.5% CAGR and reach US$50.8 Million by the end of the analysis period.
  • In the global Polyethylene Glycol (PEG) segment, USA, Canada, Japan, China and Europe will drive the 9.8% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$22.3 Million by the year 2027.

FDA Ignores RFK, Jr.'s Pleas for Vaccine Safety Oversight Concerning PEG, Suspected To Cause Anaphylaxis

Retrieved on: 
Monday, December 14, 2020

The vaccine contains polyethylene glycol (PEG) which has been identified as the likely culprit.

Key Points: 
  • The vaccine contains polyethylene glycol (PEG) which has been identified as the likely culprit.
  • CHD received a response from the FDA on December 2recommending that the organization contact the manufacturer, thus abdicating their role as regulator and protector of the people.
  • Vaccine researchers are developing a production process that also involves the utilization of PEG.
  • CHD calls on FDA to require pre-screening of all vaccine recipients for PEG allergies and to carefully monitor and publicly disclose allergic reactions associated with all vaccines.

The Polyethylene Glycol Market is set to Surpass $7.4 Billion by 2026, Says Global Market Insights Inc.

Retrieved on: 
Thursday, May 28, 2020

SELBYVILLE, Delaware, May 28, 2020 /PRNewswire/ -- Based on a Global Market Insights, Inc. report, the global Polyethylene Glycol Market size is anticipated to reach $7.4 billion by 2026, registering a CAGR of 10.8% from 2020 to 2026.

Key Points: 
  • SELBYVILLE, Delaware, May 28, 2020 /PRNewswire/ -- Based on a Global Market Insights, Inc. report, the global Polyethylene Glycol Market size is anticipated to reach $7.4 billion by 2026, registering a CAGR of 10.8% from 2020 to 2026.
  • Surging demand for water-based coatings from various industries such as automotive and construction is likely to accelerate polyethylene glycol market expansion over the projected timeframe.
  • Key reasons for Polyethylene Glycol market growth:
    2026 forecasts show the medical & pharmaceutical application segment gaining prominence:
    Based on application, the medical and pharmaceutical segment is set to emerge as a key contributor to polyethylene glycol market growth.
  • The firms are engaged in various strategic initiatives in order to gain a stronghold in the global market space.

The Polyethylene Glycol Market is set to Surpass $7.4 Billion by 2026, Says Global Market Insights Inc.

Retrieved on: 
Thursday, May 28, 2020

Surging demand for water-based coatings from various industries such as automotive and construction is likely to accelerate polyethylene glycol market expansion over the projected timeframe.

Key Points: 
  • Surging demand for water-based coatings from various industries such as automotive and construction is likely to accelerate polyethylene glycol market expansion over the projected timeframe.
  • Key reasons for Polyethylene Glycol market growth:
    2026 forecasts show the medical & pharmaceutical application segment gaining prominence:
    Based on application, the medical and pharmaceutical segment is set to emerge as a key contributor to polyethylene glycol market growth.
  • Meanwhile, increasing medical & pharmaceutical as well as personal care industries in North America are projected to drive polyethylene glycol market development over the estimated timeline.
  • The firms are engaged in various strategic initiatives in order to gain a stronghold in the global market space.

ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet

Retrieved on: 
Thursday, March 26, 2020

BAUDETTE, Minn., March 26, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Polyethylene Glycol 3350, 17g/Packet (PEG-3350).

Key Points: 
  • BAUDETTE, Minn., March 26, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Polyethylene Glycol 3350, 17g/Packet (PEG-3350).
  • This launch represents ANI's fourth new drug introduction in 2020.
  • Polyethylene Glycol 3350 is indicated for the treatment of occasional constipation.
  • ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Ferrotec Introduces the PBG-Series of Polyethylene Glycol (PEG) Based Ferrofluids

Retrieved on: 
Tuesday, January 21, 2020

BEDFORD, N.H., Jan. 21, 2020 /PRNewswire/ --Ferrotec (USA) Corporation, the US subsidiary of Ferrotec Holdings Corp., a global supplier of materials, components, and precision system solutions and the leading manufacturer of magnetic liquids, today announced the PBG-series of polyethylene glycol (PEG) based ferrofluids for bio-medical and other applications.

Key Points: 
  • BEDFORD, N.H., Jan. 21, 2020 /PRNewswire/ --Ferrotec (USA) Corporation, the US subsidiary of Ferrotec Holdings Corp., a global supplier of materials, components, and precision system solutions and the leading manufacturer of magnetic liquids, today announced the PBG-series of polyethylene glycol (PEG) based ferrofluids for bio-medical and other applications.
  • For R&D professionals, the PBG-series ferrofluids offer high magnetization and longer life than Ferrotec's EMG series of water-based ferrofluids and opens the door to new areas of research.
  • Polyethylene glycol (PEG) based ferrofluids offer high magnetization, high colloidal stability, low nonspecific binding, and biocompatibility," said Barry Moskowitz, general manager for Ferrotec's Electronic Devices Business Group.
  • More information about the PBG series ferrofluids, the EMG series and other ferrofluid products from Ferrotec can be found at ferrofluid.ferrotec.com.

Polyethylene Glycol Market Registered Healthy CAGR 5.8% by 2026 with Top Key Players International, Noah Technologies Corporation, Mil-Spec Industries Corporation, Norq, Clariant | Data Bridge Market Research

Retrieved on: 
Wednesday, December 11, 2019

Based on grade, the market is segmented into polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 400 FCC grade, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 6000 and others.

Key Points: 
  • Based on grade, the market is segmented into polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 400 FCC grade, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 6000 and others.
  • Based on application, the market is segmented into healthcare, building and construction, industrial, cosmetics/personal care and others.
  • Key insights in the report:
    About Data Bridge Market Research:
    Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
  • Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Vapen MJ's VapenClear™ Recognized by Phoenix New Times for Purity and Quality

Retrieved on: 
Thursday, October 3, 2019

Vapen MJ continues its geographic expansion of wholesale distribution through revenue and profit-sharing joint venture partnerships in multiple states and is proud to announce that its VapenClear has won the Phoenix New Times "Best of Phoenix 2019" for Best Concentrate in the Goods and Services category.

Key Points: 
  • Vapen MJ continues its geographic expansion of wholesale distribution through revenue and profit-sharing joint venture partnerships in multiple states and is proud to announce that its VapenClear has won the Phoenix New Times "Best of Phoenix 2019" for Best Concentrate in the Goods and Services category.
  • VapenClear was chosen for its outstanding quality and purity, an important differentiator at this time when consumers are searching for brands they can use with confidence.
  • According to New Times, "Cartridges sold by competitors sometimes contain such nonessential ingredients as propylene glycol, vegetable glycerin, polyethylene glycol, or coconut oil.
  • Vapen MJ expansion plans include partnering with cannabis license holders and hemp farms in multiple states within the US.

Constipation Can Spoil Even the Best Vacation. DocuSol® Products Are Developed to Help FAST!

Retrieved on: 
Wednesday, May 1, 2019

DocuSol ( www.docusolmini.com ) DocuSol is a simple mini-enema that can be used quickly and efficiently, almost anywhere.

Key Points: 
  • DocuSol ( www.docusolmini.com ) DocuSol is a simple mini-enema that can be used quickly and efficiently, almost anywhere.
  • Although vacations are meant to be relaxing and stress free, the simple change in daily routine can cause stomach and colon upset.
  • Each DocuSol mini-enema contains docusate sodium in a polyethylene glycol base and is dispensed using a soft, latex-free tube.
  • DocuSol offers the highest quality incontinence products to the federal government, national pharmaceutical wholesalers, retailers and healthcare providers across the country.

CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)

Retrieved on: 
Monday, April 22, 2019

Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq:EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code, or J-code (J9036), for BELRAPZO (bendamustine 500mL hydrochloride injection).

Key Points: 
  • Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq:EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code, or J-code (J9036), for BELRAPZO (bendamustine 500mL hydrochloride injection).
  • Eagles bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019.
  • We launched our 500mL bendamustine hydrochloride injection, to address the need in the market for our unique formulation at a lower price point.
  • Contraindication: BELRAPZO is contraindicated in patients with a history of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol.